Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

22 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Genetic heterogeneity after first-line chemotherapy in high-grade serous ovarian cancer.
Lambrechts S, Smeets D, Moisse M, Braicu EI, Vanderstichele A, Zhao H, Van Nieuwenhuysen E, Berns E, Sehouli J, Zeillinger R, Darb-Esfahani S, Cacsire Castillo-Tong D, Lambrechts D, Vergote I. Lambrechts S, et al. Eur J Cancer. 2016 Jan;53:51-64. doi: 10.1016/j.ejca.2015.11.001. Epub 2015 Dec 13. Eur J Cancer. 2016. PMID: 26693899
Exploring the clonal evolution of CD133/aldehyde-dehydrogenase-1 (ALDH1)-positive cancer stem-like cells from primary to recurrent high-grade serous ovarian cancer (HGSOC). A study of the Ovarian Cancer Therapy-Innovative Models Prolong Survival (OCTIPS) Consortium.
Ruscito I, Cacsire Castillo-Tong D, Vergote I, Ignat I, Stanske M, Vanderstichele A, Ganapathi RN, Glajzer J, Kulbe H, Trillsch F, Mustea A, Kreuzinger C, Benedetti Panici P, Gourley C, Gabra H, Kessler M, Sehouli J, Darb-Esfahani S, Braicu EI. Ruscito I, et al. Eur J Cancer. 2017 Jul;79:214-225. doi: 10.1016/j.ejca.2017.04.016. Epub 2017 May 16. Eur J Cancer. 2017. PMID: 28525846 Free article.
A Complex Network of Tumor Microenvironment in Human High-Grade Serous Ovarian Cancer.
Kreuzinger C, Geroldinger A, Smeets D, Braicu EI, Sehouli J, Koller J, Wolf A, Darb-Esfahani S, Joehrens K, Vergote I, Vanderstichele A, Boeckx B, Lambrechts D, Gabra H, Wisman GBA, Trillsch F, Heinze G, Horvat R, Polterauer S, Berns E, Theillet C, Cacsire Castillo-Tong D. Kreuzinger C, et al. Clin Cancer Res. 2017 Dec 15;23(24):7621-7632. doi: 10.1158/1078-0432.CCR-17-1159. Epub 2017 Oct 2. Clin Cancer Res. 2017. PMID: 28972047 Free article.
Characterisation of tumour microvessel density during progression of high-grade serous ovarian cancer: clinico-pathological impact (an OCTIPS Consortium study).
Ruscito I, Cacsire Castillo-Tong D, Vergote I, Ignat I, Stanske M, Vanderstichele A, Glajzer J, Kulbe H, Trillsch F, Mustea A, Kreuzinger C, Benedetti Panici P, Gourley C, Gabra H, Nuti M, Taube ET, Kessler M, Sehouli J, Darb-Esfahani S, Braicu EI. Ruscito I, et al. Br J Cancer. 2018 Aug;119(3):330-338. doi: 10.1038/s41416-018-0157-z. Epub 2018 Jun 29. Br J Cancer. 2018. PMID: 29955134 Free PMC article.
Patient-derived cell line models revealed therapeutic targets and molecular mechanisms underlying disease progression of high grade serous ovarian cancer.
Kreuzinger C, von der Decken I, Wolf A, Gamperl M, Koller J, Karacs J, Pfaffinger S, Bartl T, Reinthaller A, Grimm C, Singer CF, Braicu EI, Cunnea P, Gourley C, Smeets D, Boeckx B, Lambrechts D, Perco P, Horvat R, Berns EMJJ, Cacsire Castillo-Tong D. Kreuzinger C, et al. Among authors: cacsire castillo tong d. Cancer Lett. 2019 Sep 10;459:1-12. doi: 10.1016/j.canlet.2019.05.032. Epub 2019 May 28. Cancer Lett. 2019. PMID: 31150822
SLCO4A1 expression is associated with activated inflammatory pathways in high-grade serous ovarian cancer.
Koller S, Kendler J, Karacs J, Wolf A, Kreuzinger C, Von Der Decken I, Mungenast F, Mechtcheriakova D, Schreiner W, Gleiss A, Jäger W, Cacsire Castillo-Tong D, Thalhammer T. Koller S, et al. Among authors: cacsire castillo tong d. Front Pharmacol. 2022 Aug 29;13:946348. doi: 10.3389/fphar.2022.946348. eCollection 2022. Front Pharmacol. 2022. PMID: 36105223 Free PMC article.
22 results